Diagnostic management of benign and malignant pheochromocytoma

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 3, 2007, Pages 155-159

  Scholz, T ^a   Schulz, C ^a   Klose, S ^a   Lehnert, H ^a,b,c  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Institute for Clean Growth and Future Mobility   (United Kingdom)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Diagnostic imaging; Genetics; Metanephrines; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPAMINE; CLONIDINE; CYCLOOXYGENASE 2; FLUORODEOXYGLUCOSE; GLUCAGON; HEAT SHOCK PROTEIN 90; METADRENALIN; PENTETREOTIDE IN 111; SECRETOGRANIN II; TELOMERASE REVERSE TRANSCRIPTASE;

ADRENALECTOMY; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE URINE LEVEL; CHROMAFFIN CELL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FAMILIAL DISEASE; FAMILY HISTORY; GENE LOCUS; GENETIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSIVE CRISIS; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVIEW; SCINTIGRAPHY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIPPLE SYNDROME; TUMOR LOCALIZATION;

ADRENAL GLAND NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GENETIC TECHNIQUES; HUMANS; PHEOCHROMOCYTOMA; SENSITIVITY AND SPECIFICITY;

EID: 34247387475     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-970410     Document Type: Review

References (48)

1. Bender BU, Altehofer C, Januszewicz A, Gartner R, Schmidt H, Hoffmann MM, Heidemann PH, Neumann HP: Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome. J Clin Endocrinol Metab 1997; 82: 3356-3360
2. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG: Clinical presentation and penetrance of Pheochromocytoma/Paraganglioma syndromes. J Clin Endocrinol Metab 2006; 91: 827-836
3. Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang-Vu C, Roessner A, Lehnert H: Expression profile of the telomere complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab 2003; 88: 4280-4286
4. Bornstein SR, Gimenez-Roqueplo AP: Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Ann N Y Acad Sci 2006; 1073: 94-103
5. Bravo EL, Tagte R: Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003; 24: 539-553
6. Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford RW Jr: Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305: 623-626
7. Bravo EL, Tarazi RC, Gifford RW, Stewart BH: Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 1979; 301: 682-686
8. Senanayake PS, Denker J, Bravo EL, Graham RM: Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 1995; 96: 2503-2509
9. Edström Elder E, Xu D, Hoog A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C, Backdahl M: KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 2003; 16: 246-255
10. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr: Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004; 11: 423-436
11. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K: Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656-2666
12. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, Lenders JW: Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83: 2175-2185
13. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, Brouwers FM, Pacak K: Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 2005; 51: 735-744
14. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR: Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340: 1872-1879
15. Favier J, Plouin PF, Corvol P, Gasc JM: Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 2002; 161: 1235-1246
16. Francis IR, Korobkin M: Pheochromocytoma. Radiol Clin North Am 1996; 34: 1101-1112
17. Fujita A, Hyodoh H, Kawamura Y, Kanegae K, Furuse M, Kanazawa K: Use of fusion images of 1-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 2000; 25: 440-442
18. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau VK, Corvol P, Plouin PF, Jeunemaitre X: Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63: 5615-5621
19. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP: The genetic basis of pheochromocytoma. Front Horm Res 2004; 31: 45-60
20. Goldstein RE, O'Neill JA Jr, Holcomb GW III, Morgan WM III, Neblett WW III, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW Jr: Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229: 755-764
21. Grossman A, Pacak K, Sawka A, Lenders JW, Harlander D, Peaston RT, Reznek R, Sisson J, Eisenhofer G: Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci 2006; 1073: 332-347
22. Grossman E, Goldstein DS, Hoffman A, Keiser HR: Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension 1991; 17: 733-741
23. Ilias I, Pacak K: Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 2004; 1018: 495-504
24. Januszewicz A, Neumann HP, Lon I, Szmigielski C, Symonides B, Kabat M, Apel TW, Wocial B, Lapinski M, Januszewicz W: Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients. J Hypertens 2000; 18: 1019-1023
25. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB: Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86: 895-902
26. Kaltsas GA, Papadogias D, Grossman AB: The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 2004; 31: 61-75
27. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J, Lehnert H: Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 1997; 46: 39-44
28. Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Phaeochromocytoma. Lancet 2005; 366: 665-675
29. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, Eisenhofer G: Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995; 123: 101-109
30. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G: Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-1434
31. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H: Codon-specific development of peochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005; 90: 3999-4003
32. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Keiser HR, Neumann RD: Iodine-131- metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993; 34: 173-179
33. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke C, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-1466
34. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C: Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292: 943-951
35. Neumann HP, Reincke M, Bender BU, Elsner R, Janetschek G: Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 1999; 84: 2608-2610
36. NIH NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements 2002; 19: 1-25
37. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS: 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001a; 38: 6-8
38. Pacak K, Eisenhofer G, Ilias I: Diagnostic imaging of pheochromocytoma. Front Horm Res 2004; 31: 107-120
39. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G: A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 2001b; 86: 3641-3646
40. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS: Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001c; 20: 315-329
41. Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL: Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology 1987; 165: 89-93
42. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P: Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86: 5615-5619
43. Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J: VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 2003; 111: 458-464
44. Sawka AM, Gafni A, Thabane L, Young WF Jr: The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab 2004a; 89: 2859-2866
45. Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M, Young WF Jr: A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord 2004b; 4: 2
46. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC: Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35-41
47. 111In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86: 685-693
48. Yon L, Guillemot J, Montero-Hadjadje M, Grumolato L, Leprince J, Lefebvre H, Contesse V, Plouin PF, Vaudry H, Anouar Y: Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. J Clin Endocrinol Metab 2003; 88: 2579-2585